Clinical footwork pays off in Tango’s PDAC combo phase I/II
Summary
Tango Therapeutics reported encouraging phase I/II data for vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors for MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer. The company plans to meet with the FDA soon to discuss the next clinical and pivotal development steps. The article highlights the strength of the data and its potential to support advancement toward later-stage trials. This is a drug-development milestone rather than a software or operational technology announcement.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected